Startseite › Nierenkrebs (Nierenzellkarzinom) › Kalifornien › Los Angeles
Klinische Studien zu Nierenkrebs (Nierenzellkarzinom) in Los Angeles, CA
20 Studien zu Nierenkrebs (Nierenzellkarzinom) suchen Teilnehmer an Standorten in und um Los Angeles (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Teilnehmer gesuchtPhase 1
- Cedars-Sinai Medical Center, Los Angeles
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Teilnehmer gesuchtPhase 2
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Teilnehmer gesuchtPhase 1/2
- University of Southern California, Los Angeles
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Teilnehmer gesuchtPhase 2
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
Teilnehmer gesuchtPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Teilnehmer gesuchtPhase 3
- Los Angeles General Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Teilnehmer gesuchtPhase 1
- University of Southern California, Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer, Los Angeles
- Cedars-Sanai Medical Center, Los Angeles
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
Teilnehmer gesuchtPhase 1/2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study of MGC026 in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- The Angeles Clinic and Research Institute, Los Angeles
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Teilnehmer gesuchtPhase 3
- USC Norris Comprehensive Cancer Center ( Site 0126), Los Angeles
- Cedars-Sinai Medical Center ( Site 0112), Los Angeles
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Teilnehmer gesuchtPhase 1/2
- California Research Institute, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Teilnehmer gesuchtPhase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Teilnehmer gesuchtPhase 1
- Start Lacn, Los Angeles
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Southern California, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- UCLA Department of Medicine, Los Angeles
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Teilnehmer gesucht
- Oncology Institute for Hope and Innovation, Los Angeles
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Teilnehmer gesuchtPhase 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study of VET3-TGI in Patients With Solid Tumors
Teilnehmer gesuchtPhase 1
- USC/Norris Comprehensive Cancer Center, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Teilnehmer gesuchtPhase 1/2
- UCLA Medical Center, Los Angeles
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Teilnehmer gesuchtPhase 3
- Keck Medicine of USC Koreatown, Los Angeles
- Los Angeles County-USC Medical Center, Los Angeles
- USC / Norris Comprehensive Cancer Center, Los Angeles
- und 2 weitere
Nierenkrebs (Nierenzellkarzinom)-Studien in anderen Städten
- Houston, TX35 Studien
- New York City, NY27 Studien
- Dallas, TX23 Studien
- Nashville, TN23 Studien
- St. Louis, MO23 Studien
- Boston, MA16 Studien
- Baldwin Park, CA16 Studien
- Philadelphia, PA15 Studien
- Pittsburgh, PA15 Studien
- Queens, NY15 Studien
- Rochester, MN14 Studien
- Jacksonville, FL14 Studien
Weitere Studien in Los Angeles
- Nichtkleinzelliges Lungenkarzinom87 Studien
- Krebs (alle Arten)74 Studien
- Brustkrebs73 Studien
- Prostatakrebs61 Studien
- Kolorektales Karzinom59 Studien
- Metastasierender Krebs57 Studien
- Eierstockkrebs50 Studien
- Lungenkrebs45 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich42 Studien
- Bauchspeicheldrüsenkrebs35 Studien
- Endometriumkarzinom34 Studien
- Melanom34 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.